Question of the Day – Friday March 2, 2018

Question- Cetuximab is an epidermal growth factor receptor (EGFR) monoclonal antibody used to treat head and neck and advanced colorectal cancer. What are the potential ocular toxicities associated with the use of this drug?

Answer- The cited reference notes, “Multiple different ocular toxicities have been reported with the use of cetuximab, including corneal erosions, poliosis, eyelash trichomegaly, punctate keratitis, conjunctivitis, eyelid dermatitis and blepharitis.” (Stjepanovic N et al. Ocular toxicities of MEK inhibitors and other targeted therapies. 2016 Anns Onc 27:998-1005.)